Mirum Pharmaceuticals, Inc. (MIRM) Guidance & Earnings Results
On 2026-08-05 Mirum Pharmaceuticals, Inc. raised guidance: "FY2026 net product sales guidance raised to $680M-$700M from prior…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MIRMMirum Pharmaceuticals, Inc.Follow MIRM — free
—
Price chart with a free account
- Market cap
- 5.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 5 Aug 26 | Raised | FY2026 net product sales guidance raised to $680M-$700M from prior range · full year |
| 6 May 26 | Raised | FY2026 net product sales guidance raised to $660-$680M · full year |
| 25 Feb 26 | Raised | 2026 guidance $630-650M vs 2025 actual $521.3M |
| 12 Jan 26 | Raised | 2026 net product sales guidance $630-650M vs 2025 preliminary $520M |
| 4 Nov 25 | Raised | Revenue guidance raised to $500-510M from prior range · full year |
| 6 Aug 25 | Raised | FY2025 revenue raised to $490-510 million from prior range (not explicitly stated but implied increase). · full year |
Mirum Pharmaceuticals, Inc. — questions
- What guidance did Mirum Pharmaceuticals, Inc. give?
- On 2026-08-05: "FY2026 net product sales guidance raised to $680M-$700M from prior range"
- When does Mirum Pharmaceuticals, Inc. report earnings?
- Mirum Pharmaceuticals, Inc.'s next earnings report is expected on 2026-11-17.
Every figure on this page comes from Mirum Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.